Hepatitis C

Researchers report promising results from the QUARTZ-I study that assessed the efficacy of the 3D regimen combined with sofosbuvir in treatment-experienced patients with HCV genotype 1 infection.

Results from the ION-3 trial showed that the rapidity and durability of viral suppression achieved with ledipasvir-sofosbuvir therapy allows a shorter treatment course of 8 weeks in genotype 1, treatment-naïve, non-cirrhotic patients.

A recent study looked to shed light on the long-researched belief that caffeine decreases the risk of advanced hepatic fibrosis in people with hepatitis C.

With May officially Hepatitis Awareness Month, there is an active campaign underway designed to encourage people to get tested for hepatitis C. May 19 has been designated National Hepatitis Testing Day in the US for the fifth year running.

Excessive alcohol consumption not only increases the risk of liver disease in people with hepatitis C, but it also increases the risk of death.

When a patient is dying, it can be difficult to know what to say to them. Here are a few tips and approaches that I have gathered from experts that I hope will help you get through those hard conversations while continuing to provide the best possible care to your patient.

Being a good doctor is hard work, especially considering the current state of our health care system. Some doctors, however, are simply bad news. And because most doctors today have comparable education and credentials, bad doctors don’t exactly stick out like sore thumbs.

Researchers in Italy found that some patients who are successfully treated for the hepatitis C virus tend to live as long as others in the general population not infected with the disease.

Researchers assessed the risk of developing hepatocellular carcinoma among patients who have been cured of the hepatitis C virus.

Researchers applied a new technique to investigate the hepatitis C virus (HCV) genome, and gained insights into the extreme mutability of the virus.

Under the threat of lawsuits, seven major commercial insurers doing business in New York will now cover direct acting antivirals for patients with HCV infection, as will NY's Medicaid program. The plans will also stop denying coverage to patients who abuse drugs or alcohol.

The US Food and Drug Administration approved a supplemental New Drug Application submitted by drug maker AbbVie for Viekira Pak without ribavirin to treat patients with chronic hepatitis C genotype 1b and compensated cirrhosis.

Why didn't dozens of young patients diagnosed with hepatitis C get treatment in Princeton, NJ? New CDC study offers reasons.

Patients with hepatitis C were two to five times more likely to develop some types of head and neck cancers, according to a study conducted by the University of Texas MD Anderson Cancer Center in Houston.

An Australian physician is sending generic DAAs made in China and India to patients with hepatitis in the US. It's part of an NIH-approved clinical trial.

Layoffs are tough. But, the economic downturn, lower insurance reimbursements, increased business expenses and the expectation that medical practices “do more with less†may make layoffs unavoidable.

A team from Germany found patients with acute HCV infection could be cured in six weeks with DAA treatment, half the recommended time.

Nurse practitioners with three hours training were better than specialists or primary care providers at getting HCV patients to complete their DAA regimens, Washington, DC area researchers found.

Direct-acting antivirals can cure hepatitis C. But in patients who had also had liver cancer, the drugs appear to result in an alarmingly high rate of cancer recurrence.

A recent study in the United Kingdom looked at the 6-month outcomes of those with hepatitis C cirrhosis on antiviral treatment.

Investigational RG-101 could shorten HCV treatment with direct-acting antivirals to four weeks, researchers report in a phase 2 study.

Work being done to treat and cure hepatitis C today could make it almost a non-issue for future generations, thanks to groups like the World Health Organization (WHO) and others putting the focus on parts of the world that need help in this area the most.

As hepatitis C becomes a largely curable condition, work is being done to ensure that people around the world get the same level of treatment no matter where they live. That effort is being supported thanks to new guidelines from the World Health Organization (WHO).

A combination of sofosbuvir, velpatasvir, and GS-9857 has been shown safe and effective in treating hepatitis C genotype 1 infection, researchers from the Texas Liver Institute reported.

With the advent of direct acting antivirals for hepatitis C, having the virus is no barrier to becoming a liver donor. A study showed that because of the drugs, HCV positive patients who get HCV positive livers do just fine.

Men who are HIV positive and who have sex with other men (MSM) are experiencing an epidemic of sexually transmitted hepatitis C virus (HCV).

A new direct acting antiviral combo for hepatitis c infection is more effective than sofosbuvir and peg-interferon plus ribavirin.

Direct acting antivirals have been miracle drugs for many, but a Spanish study found they can make things worse in patients with advanced liver disease.

Cirrhosis is not a new condition in the medical community, but researchers are looking at regions where the condition may be more common and how changes in policy regarding alcohol could help prevent more cases of the condition in the future.

While many forms of hepatitis C are now nearing curability, there are some genotypes which are harder to treat and some patient populations proving harder to reach. Research is being done on several fronts to address both issues.